. Matrix remodeling in experimental and human heart failure: a possible regulatory role for TIMP-3. Am J Physiol Heart Circ Physiol 284: H626-H634, 2003. First published October 10, 2002 10.1152/ajpheart.00684.2002In the failing heart, an imbalance in matrix metalloproteinases (MMPs) and their biological regulators, the tissue inhibitors of MMPs (TIMPs), may result in cardiac dilatation from matrix degradation. We hypothesized that a reduction of myocardial TIMP-3 is associated with adverse matrix remodeling in both human and experimental heart failure. Cardiomyopathic hamsters at age 15 wk (normal), 25 wk (compensated stage), and 35 wk (overt failure) were compared with age-matched normal controls. MMP activity (gelatinase bioassay) was increased in cardiomyopathic hearts (P ϭ 0.03) and peaked during the transition to overt heart failure. TIMP-3 content (immunoblot) was decreased compared with normal controls (74 Ϯ 5% at 25 wk, 69 Ϯ 10% at 35 wk; P ϭ 0.001) and its reduction was associated with increased MMP activity (r ϭ Ϫ0.6; P ϭ 0.004). TIMP-1 increased progressively (P ϭ 0.001), whereas TIMP-2, TIMP-4, and MMP protein levels were unchanged. Myocardial collagen (hydroxyproline content) increased with time during the progression to end-stage cardiac failure (P Ͻ 0.0001). Collagen synthesis ([ 14 C]proline uptake) was elevated in cardiomyopathy at 15 and 25 wk (P Ͻ 0.05). The collagen cross-linking ratio (insoluble:soluble collagen) was reduced (P ϭ 0.003) as the left ventricle dilated. By confocal microscopy restricted to viable myocardium, collagen content was reduced (P ϭ 0.04) with fragmentation (P Ͻ 0.0001) and thinning (P ϭ 0.003) of perimysial collagen fibers. Similarly, patients with end-stage congestive heart failure (n ϭ 7) compared with nonfailing controls (n ϭ 2) had elevated gelatinase MMP activity (P ϭ 0.02) associated with isolated reductions in TIMP-3 (55 Ϯ 5% of normal; P ϭ 0.003). Reductions of TIMP-3 parallel adverse matrix remodeling in the cardiomyopathic hamster and the failing human heart.
IN RESPONSE TO INJURY, myocytes and their surrounding extracellular matrix reorganize resulting in progressive ventricular dilatation, wall thinning, and cardiac dysfunction (37) . In both ischemic and nonischemic dilated cardiomyopathy (DCM), cardiac remodeling mediates the transition from compensated to decompensated heart failure (22, 37) . Therapies that reduce mortality for patients with heart failure invariably produce favorable effects on the remodeling process and thereby limit disease progression (27) . Identifying the molecular regulators of the disruptive remodeling process will facilitate the development of novel therapies for the growing number of patients at risk of congestive heart failure.
The myocardial matrix provides both structural support and a dynamic microenvironment where molecular cues may interact to regulate tissue remodeling (21, 35) . In the failing heart, the myocardial matrix is degraded by matrix metalloproteinases (MMPs) resulting in diminished structural support, altered ventricular geometry, and contractile dysfunction (32) . The tissue inhibitors of metalloproteinases (TIMPs) are endogenous MMP inhibitors that regulate and maintain matrix homeostasis when present in the dynamic interstitial compartment. TIMPs directly inhibit the disruptive MMPs and have been implicated in the regulation of cell shape, function, and survival independent of their MMP-inhibitory effects (20) . In light of these diverse biological roles, the TIMPs may play a central role in cardiac remodeling. Human studies have been limited by end-stage tissue (17, 28, 39) such that a comprehensive analysis of MMP-TIMP interactions and matrix remodeling during the progression of heart failure is not currently available.
The normal human heart expresses all of the four known TIMP species (TIMP-1, -2, -3, and -4). Although the TIMPs are altered during the progression of human heart failure, a consistent and clear pattern has yet to be defined (23) . We hypothesized that a specific profile of TIMPs is associated with adverse remodeling of the matrix in both human and experimental heart failure. To investigate this hypothesis, we examined the profile of TIMPs and the associated changes in matrix content, organization, and turnover during the temporal progression of heart failure in the cardiomyopathic hamster. To validate these findings, results were compared with patients with end-stage heart failure. Revised 1985) . The Syrian hamster with genetic cardiomyopathy (BIO 53.58 hamster, Bio Breeders; Fitchburg, MA) was used as our heart failure model. Age-matched normal FVG Syrian hamsters served as controls (Charles River; Quebec, Canada). A total of 30 hamsters were used to complete this study (DCM, n ϭ 21; normal, n ϭ 9).
MATERIALS AND METHODS

Experimental
Hamsters were euthanized by anesthetic overdose. Hearts were quickly excised and arrested in ice-cold phosphatebuffered saline (PBS). A small portion of the anterior free wall of the left ventricle (LV) was snap-frozen in liquid nitrogen and stored at Ϫ80°C for enzyme analysis. The remaining portion of the LV was coarsely minced and incubated in DMEM (GIBCO) containing fetal calf serum (1%, GIBCO), ascorbic acid (50 g/ml), and [
14 C]proline (0.5 Ci/ ml) at 37°C, 5% CO2, to permit incorporation into newly synthesized collagen (3). After 6 h, the samples were repeatedly washed four times in PBS and further treated as described below.
Human samples. The Institutional Review Board approved our protocol for consent to use human tissue for these studies. LV samples (n ϭ 2) were obtained from cardiac donors whose hearts were suitable for transplantation but for which no recipient was available. Patients (n ϭ 7) in end-stage congestive heart failure (LV ejection fraction Ͻ20%, New York Heart Association functional class IV), with ischemic cardiomyopathy (n ϭ 3) or DCM (n ϭ 4), were included in the present study. Samples of the anterior LV were collected during cardiac surgery at the time of cardiac transplantation or insertion of a mechanical assist device. Transmural samples were collected avoiding obvious areas of scar or infarction. The samples were immediately snap-frozen in liquid nitrogen and stored at Ϫ80°C until use.
Assessment of MMP activity. Snap-frozen samples of the LV anterior wall were pulverized in liquid nitrogen and extracted in ice-cold extraction buffer (20 l/mg tissue) containing (in mM) 50 Tris ⅐ HCl, 150 NaCl, 10 CaCl 2 and 0.2 NaN3, and 0.01% Triton X-100 (pH 7.6) and stirred for 30 min. After centrifugation, the supernatant was collected and the pellet was reextracted twice more. The supernatant from each extraction step was pooled and stored at Ϫ80°C. Gelatinase MMP activity was determined with a commercial bioassay kit (Chemicon International; Temecula, CA). MMP activity in the samples was assessed without preactivation and compared with p-aminophenylmercuric acetate-activated purified human MMP-9 (Chemicon International), which was used as a standard. MMP activity is expressed as the equivalent activity of activated MMP-9. To distinguish MMP activity from nonspecific gelatinase activity, GM6001 (nonspecific MMP inhibitor) was added to a random sample in each group. MMP activity was ϳ90% of the total gelatinase activity.
Quantification of MMPs and TIMPs. The relative abundance of MMPs and TIMPs was examined in LV myocardial extracts using standard immunoblotting procedures. In brief, extracts containing equal amounts of protein were fractionated by 10% SDS-PAGE and electrotransferred onto a polyvinylidene difluoride membrane (Bio-Rad). The membranes were blocked with 5% (vol/vol) nonfat dry milk in 20 mM Tris ⅐ HCl (pH 7.5), 500 mM NaCl, and 0.1% Tween 20 for 1 h at room temperature. Incubation was performed overnight at 4°C with polyclonal rabbit anti-human antibodies for TIMP-1 (1:5,000), TIMP-2 (1:3,000), TIMP-3 (1:500), TIMP-4 (1:3,000), MMP-2 (1:5,000), and MMP-9 (1:2,000, Chemicon International). Subsequently, the membranes were washed with Tris-NaCl-Tween 20 and incubated with a goat antirabbit IgG horseradish peroxidase conjugate (1:2,000, Santa Cruz Biotech) for 1 h at room temperature. Membranes were developed with enhanced chemiluminescence reagent (Amersham Pharmacia) and quantified by image analysis. For TIMP-2 and TIMP-3, only the band that migrated with the positive controls was quantified. The results were presented as the percentage of change compared with nonfailing controls, whose means were arbitrarily set as 100%.
Collagen content, cross linking, and synthesis. Collagen content in the LV was determined by using the method of Strauss and colleagues (36) . The minced myocardial sample was divided into two portions. In the first portion, samples were digested overnight by a cyanogen bromide (CNBr) treatment (50 mg/ml in 70% formic acid, 1.0 ml per 50 mg tissue, under N 2), which solubilized all proteins except for crosslinked collagen by cleaving methionine bonds. The supernatant, which contained fragments of collagen and other proteins, was dried and hydrolyzed in 6 N HCl at 110°C for 24 h. The remaining portion of myocardium was dried and hydrolyzed in 6 N HCl at 110°C for 24 h omitting the prior CNBr digestion.
Collagen content was measured by determining the hydroxyproline content of the hydrolyzate. Hydroxyproline determination of the soluble residue after CNBr treatment determined the soluble collagen fraction. Hydroxyproline determination of the soluble residue after acid digestion without prior CNBr treatment determined total myocardial collagen (soluble and insoluble collagen). The CNBr-insoluble fraction was calculated as the difference between total collagen and soluble collagen. With the use of this value, the ratio of CNBr-insoluble collagen to soluble collagen was calculated and used as an index of collagen cross-linking.
The rate of collagen synthesis was determined by the rate of [
14 C]proline incorporation into myocardial collagen (36) . Hydroxylation of proline residues to hydroxyproline in collagen is a posttranslational event. To this end, the CNBrdigested HCl hydrolyzed myocardial samples were assayed for [
14 C]hydroxyproline and expressed as counts per minute per gram of myocardium.
Confocal microscopy of matrix structure. To evaluate the organization of the fibrillar collagen matrix during the transition to decompensated heart failure, LV sections from cardiomyopathic and normal hamsters at 25 wk of age (n ϭ 3 per group) were fixed, processed with graded alcohols, embedded in paraffin, cut into 10-to 15-m-thick sections, and stained with 0.1% picrosirius red. To enhance the contrast between myocytes and collagen, sections were treated with 0.2% phosphomolybdic acid (pH 1.8-2.2) before being stained. Sections were imaged with the use of a laser scanning confocal system (model MRC 1024, Bio-Rad). Fields were randomly selected from the midmyocardium, excluding large epicardial arteries and veins, cutting or compression artifact, and any obvious focal areas of scar. Only regions that appeared as viable, functional myocardium devoid of cellular necrosis and associated scar were selected for confocal analysis (Fig. 1A) . Four random fields were obtained from each of two transverse LV segments. Three hearts for each group were used for confocal analysis to yield a total of 24 images per group. The stained LV sections were then digitized at a final magnification of ϫ600 and analyzed using an image analysis system (Scion Image, NIH Software). Image analysis was performed to quantify these parameters in blinded fashion. For each image, the total collagen area fraction and the perimysial collagen fiber length and diameter were measured. The average collagen fiber diameter was calculated from 7 to 10 measurements along each fiber.
Statistical analysis. Results are presented as means Ϯ SE. Comparison between groups was performed by one-way ANOVA. If the F ratio was significant, pairwise tests of individual group means were compared using the StudentNewman-Keuls test. All statistical procedures were performed with SAS software (SAS Institute; Cary, NC). The critical ␣-level for these analyses was set at P Ͻ 0.05.
RESULTS
MMP gelatinase activity. Gelatinase (MMP-2 and MMP-9) activity was assessed by a commercial plate assay, which allows determination of MMP activity in the presence of native TIMP species. MMP activity was elevated above normal levels in all ages of DCM and peaked significantly at 25 wk during the transition from compensated dysfunction to overt failure (Fig.  1B) . MMP activity was three times greater than the activity in normal myocardium at 25 wk of age.
Protein levels of MMPs and TIMPs. Protein levels of myocardial MMP-2, MMP-9, and TIMP-1 to TIMP-4 were determined by Western blotting with appropriate commercially available antibodies. The mean levels of myocardial MMP-2 and MMP-9 were not significantly different from normal age-matched controls. Although MMP activity was elevated in DCM hearts, the protein levels of these MMPs were not different between normal and failing hearts at any age.
Mean protein levels of myocardial TIMP-2 and TIMP-4 were not significantly different from normal age-matched controls. In contrast, TIMP-1 and TIMP-3 differed significantly between groups and with the progression of heart failure over time (Fig. 2, A-C) . At 15 wk, when myocardial structure and function were grossly normal, both TIMP-1 and TIMP-3 were comparable to normal controls. With ventricular dilatation and dysfunction (25 wk or greater), TIMP-1 progressively increased above normal controls, which positively correlated with MMP activity (r ϭ 0.6, P ϭ 0.002). Myocardial TIMP-3 levels were decreased in association with altered ventricular geometry and myocardial dysfunction and were inversely related to MMP activity (r ϭ Ϫ0.6, P ϭ 0.004) supporting their specific role in inhibiting in vivo MMP activation (Fig.  2, D and E) .
Myocardial collagen content, synthesis, and crosslinking. Collagen content was significantly increased in the DCM group compared with age-matched controls (Fig. 3A) . In DCM hearts, collagen content increased in parallel to the progression of heart failure.
Collagen cross links maintain structural support within the myocardium and were significantly reduced compared with normal myocardium during the course of LV dilatation (15 and 25 wk) (Fig. 3B) . Collagen cross-linking was elevated above normal levels at endstage cardiomyopathy (35 wk) when the chamber was severely dilated and failing. In contrast, collagen crosslinking was not different in normal myocardium at 15, 25, and 35 wk, respectively.
Collagen synthesis was elevated early (15 wk) and remained elevated during compensatory LV dysfunction (25 wk) returning to normal at end-stage failure (35 wk; Fig. 3C ). Collagen synthesis did not differ at 15, 25, and 35 wk in normal myocardium. Confocal microscopy and quantitative image analysis. Confocal microscopy was performed to assess the architecture of the myocardial fibrillar collagen network in hamsters at the time of TIMP-3 deficiency (25 wk) before end-stage disease and was compared with age-matched normal controls. Images were selected exclusively from areas of viable myocardium avoiding focal areas of scar and large blood vessels. In the DCM group, all hamsters showed marked disruption of the structure of the fibrillar collagen matrix (Fig. 4) . By quantitative image analysis (Table 1) , the local collagen matrix content was significantly reduced in the DCM group indicating a loss of matrix components due to excessive degradation. The length and diameter of the perimysial collagen fibrils surrounding the myofibrils was reduced in the DCM group indicating fragmentation of the fibrillar collagen network.
Comparative analysis of human samples. Results of the comparative analysis of end-stage human failing myocardium are presented in Fig. 5 . MMP activity was increased in human patients with congestive heart failure (n ϭ 7) compared with nonfailing controls (n ϭ 2). TIMP-3 was decreased in patients with congestive heart failure compared with nonfailing controls, whereas the content of the remaining TIMP species, including TIMP-1, were not significantly different.
DISCUSSION
The extracellular matrix may play a central role in the complex process of myocardial remodeling. Reorganization of the myocardial matrix alters the structural support for cardiomyocytes as well as the environmental cues necessary for their function and survival (21, 35) . In the present study, we provide a comprehensive analysis of matrix remodeling during the temporal progression of remodeling in the cardiomyopathic hamster model of heart failure and compared these results with those obtained in patients with end-stage heart failure. Our data suggests that reductions in myocardial TIMP-3 parallel significant changes in matrix turnover, content, and structure and may contribute to decompensation in the failing heart.
Experimental model. The Syrian cardiomyopathic hamster strain used in this study has a genomic deletion of the ␦-sarcoglycan gene (26) that disrupts the vascular smooth muscle cell sarcoglycan-sarcospan complex (29) , thus inducing microvascular spasm (10). by immunoblotting, TIMP-3 was decreased during the transition to decompensation at 25 wk (74 Ϯ 5% of normal) and during end-stage disease at 35 wk (69 Ϯ 10% of normal; *P ϭ 0.001), whereas TIMP-1 increased progressively (P ϭ 0.001). Normal (n ϭ 5; n ϭ 1 at 15 wk, n ϭ 2 at 25 wk, n ϭ 2 at 35 wk) and DCM (n ϭ 6 at 15 wk, n ϭ 6 at 25 wk, and n ϭ 6 at 35 wk) values are shown. D and E: reductions in TIMP-3 were associated with increased MMP activity suggesting that TIMP-3 regulates cardiac matrix turnover in the failing heart. In contrast, the endogenous MMP inhibitor TIMP-1 increased in association with elevated MMP activity perhaps indicating an inadequate compensatory response to elevated matrix degradation.
An accumulation of focal myocardial infarcts results in a reproducible, irreversible, and gradually progressive congestive heart failure (14) . In our experience, LV function and structure is grossly preserved at 15 wk of age, whereas ventricular dysfunction with significant LV dilatation is evident by 25 wk, but without overt failure (compensated stage) (25) . However, by 35 wk, the LV is severely dilated with compromised function and overt failure (decompensated stage). Remodeling of the myocardial matrix has been studied extensively in this hamster strain by using similar time points for comparison (9, 11, 24) . The BIO 53.58 strain lacks a hypertrophic response similar to patients with DCM. In fact, ␦-sarcoglycan gene mutations occur in human patients and can result in DCM (38) . Thus the ␦-sarcoglycan-deficient hamster is similar to human cardiomyopathy (13), both acquired (ischemic) and idiopathic (inherited) dilated forms, and is thus an appropriate model to study the process of LV remodeling.
Matrix turnover. In the cardiomyopathic hamster, MMP gelatinase activity was elevated during the temporal progression of heart failure. These data support the concept of excessive MMP activity in failing hearts (32, 33) . However, the majority of previous studies employed techniques that were unable to account for the influence of TIMPs on overall MMP activity. In the present study, gelatinase activity was assessed using a bioassay that, unlike traditional gelatin zymography, measures MMP activity in the presence of and relative 3 . A: myocardial hydroxyproline (HPRO), a measure of collagen content, increased with the progression to overt failure in cardiomyopathic hamsters (*P Ͻ 0.0001). Normal (n ϭ 5; n ϭ 1 at 15 wk, n ϭ 2 at 25 wk, n ϭ 2 at 35 wk) and DCM (n ϭ 6 at 15 wk, n ϭ 6 at 25 wk, and n ϭ 6 at 35 wk) values are shown. B: cross-linked collagen (ratio of insoluble to soluble collagen) was reduced at 15 and 25 wk (P ϭ 0.003) in cardiomyopathic hamsters in parallel to LV dilatation. Normal (n ϭ 5; n ϭ 1 at 15 wk, n ϭ 2 at 25 wk, n ϭ 2 at 35 wk) and DCM (n ϭ 6 at 15 wk, n ϭ 6 at 25 wk, and n ϭ 6 at 35 wk) values are shown. C: collagen synthesis was determined by the rate of [
14 C]proline incorporation and was elevated in cardiomyopathy before the onset of overt failure (*P Ͻ 0.05). Normal (n ϭ 3 at 15 wk, n ϭ 3 at 25 wk, n ϭ 3 at 35 wk) and DCM (n ϭ 6 at 15 wk, n ϭ 6 at 25 wk, and n ϭ 6 at 35 wk) values are shown. CPM, counts per minute.
to their natural inhibitors and, hence, is more likely to reflect in vivo MMP and TIMP activity. The presence of TIMPs in the samples was confirmed by immunoblotting ( Fig. 2A) . Our data suggests that when the influence of TIMP inhibition is considered, MMP activity is still in excess of normal and is particularly elevated during the transition to overt failure.
TIMP regulation of matrix remodeling. MMP activity can be elevated from increased MMP content and/or increased MMP activation (35) . Interestingly, MMP-2 and MMP-9 protein abundance was not significantly different from normal controls, suggesting that increased MMP activation in hamsters with cardiomyopathy elevates MMP activity. These data suggest a loss of endogenous inhibitory control, perhaps from a reduction in TIMPs. The four TIMP species all bind and inactivate the various MMPs, including MMP-2 and MMP-9, but with different affinities. TIMP-3 is a more potent inhibitor of MMP-9 than the other TIMPs (35). In our study, whereas TIMP-2 and TIMP-4 levels were unchanged, TIMP-3 was reduced in parallel to significant alterations in the matrix turnover, content, and structure. The reorganization of matrix components was temporally associated with LV dilatation and the loss of function. Whereas no clear pattern of overall TIMP expression has been defined in heart failure (23), reductions of TIMP-3 have been consistently reported in end-stage human heart failure (17, 39) and in ventricular hypertrophy after experimental aortic banding (31) . In our study, TIMP-3 was significantly reduced during the progression of hamster cardiomyopathy and in patients with end-stage congestive heart failure. In contrast to TIMP-1, TIMP-3 abundance was negatively correlated with gelatinase activity, which supports its role in regulating matrix degradation.
TIMP-1 was markedly elevated at both the compensated and decompensated stages in hamster cardiomyopathy. In human heart failure, both increased and decreased TIMP-1 levels compared with nonfailing controls have been reported (23, 28) and our data support this variable pattern. Inflammatory cytokines, such as tumor necrosis factor-␣ (TNF-␣) and interleukin-1, cause a dramatic reprogramming of TIMP expression profiles in cardiomyocytes. In response to TNF-␣, TIMPs are differentially regulated such that TIMP-1 expression is increased, whereas TIMP-3 is downregulated (19) . In support, TIMP-1 and TIMP-3 were negatively correlated with each other in the hamster (r ϭ Ϫ0.7; P Ͻ 0.05). TIMP-1 is known to inhibit gelatinase MMPs, but under certain conditions TIMPs have been reported to stabilize MMPs and increase their activation (43) . However, it is more likely that TIMP-1 was elevated as a compensatory response to decreased TIMP-3 and increased MMP activity, but inadequate to control overall MMP activation. MT1-MMP is a local cell surface MMP induction/activation system that increases MMP-mediated matrix degradation in the failing heart and is upregulated Ͼ10-fold in human cardiomyocytes isolated from failing myocardium (34) . TIMP-3, but not TIMP-1, can inhibit MT1-MMP (42) . As such, the upregulation of TIMP-1 in response to the downregulation of the more potent TIMP-3 may be inadequate to prevent the activation of MMPs that degrade the cardiac matrix.
Matrix content and organization. In the failing heart, both the content and organization of fibrillar collagen are believed to influence myocardial structure and function (23, 37) . MMP-TIMP stoichiometery may regulate the balance of matrix elements and maintain chamber geometry and contractile function. Although an accumulation of myocardial collagen (fibrosis) is frequently associated with LV dilatation (37) , so too is a degradation of the fibrillar collagen network (33) . This apparent contradiction attests to the complexity of the remodeling process. In cardiomyopathic hamsters, total myocardial collagen content increased with the progression of LV dilatation to failure. In addition, myocardial collagen synthesis was elevated in disease, supporting an increased myocardial collagen content. In contrast, by a laser confocal microscopic analysis confined to viable myocardial segments avoiding areas of focal scar, we demonstrate that regional collagen content is indeed reduced, with significant collagen Values are means Ϯ SE. DCM, dilated cardiomyopathy. Quantitative image analysis of the fibrillar collagen network in viable myocardial regions of the cardiomyopathic hamster at 25 wk (n ϭ 3) compared with age-matched controls (n ϭ 3) indicate reduced collagen content with significant fragmentation and thinning of perimysial fibers.
fibril thinning and fragmentation indicating degradation of the fibrillar collagen network ( Table 1 ). The appearance of the degraded fibrillar collagen network was similar to reports of human DCM (41) . Light microscopic analysis indicated that most of the new collagen was directed to scar formation in areas of cell necrosis as replacement fibrosis (Fig. 1A) . In contrast, matrix degradation appeared to occur in the viable myocardial regions remote from areas of focal necrosis and scar formation (Fig. 4) . These regional differences in matrix turnover may explain how collagen breakdown and increased collagen content can occur simultaneously.
A reduction in collagen cross-linking is associated with progressive LV dilatation in experimental models of heart failure (44) and patients with cardiomyopathy (15), presumably resulting from MMP-mediated disruption of mature collagen fibrils. In cardiomyopathic hamsters, collagen cross-linking was dramatically reduced during the period of significant LV dilatation (between 15 and 25 wk of age) and increased at endstage disease (35 wk) , when the ventricle is noncompliant and decompensated. These findings support the role of organized collagen in preventing chamber dilatation and indicate, along with other experimental models of heart failure (8, 44) , that decreased collagen cross-linking does parallel LV dilatation. The reduction in collagen cross-linking parallels the increased synthesis of collagen at 15 and 25 wk, with increased crosslinking at 35 wk when collagen synthesis is attenuated. These data support the notion that newly synthesized collagen is unable to form stable cross-links and requires time to mature and stiffen.
TIMP-3 and cardiac remodeling: a novel role. Unlike its counterparts, TIMP-3 is unique in that it binds to and is localized within the extracellular matrix (2, 16) , where it acts to neutralize MMPs, inhibit TNF-␣-converting enzyme (TACE) (1, 4) , and influence cell survival (5, 12, 43) . In failing myocardium, reductions of TIMP-3 may contribute to cardiac remodeling by elevating MMP activity, increasing TNF-␣ activation, and promoting cell death (Fig. 6 ). These unique properties may afford TIMP-3 a key regulatory role in the process of myocardial remodeling.
Our data indicate that the magnitude of reduction for TIMP-3 was moderate, but the biological consequences on MMP activity were substantial. The profound biological effects of TIMP-3 reductions may be a consequence of its broad inhibitory profile combined with its binding and localization to the extracellular matrix where it can directly influence matrix turnover (2, 16, 43) . The striking increase in TIMP-1 appears to occur in response to TIMP-3 reductions and increased MMP activity. Despite its substantial elevation, TIMP-1 did not prevent elevated MMP activity in the failing heart. In contrast to the potent TIMP-3, soluble TIMP-1 is unable to bind within the matrix microenvironment where MMPs are activated. In addition, TIMP-1 is incapable of regulating MT1-MMP, an important cell surface activator of MMPs that is normally controlled by adjacent TIMP-3 molecules.
The unique and profound effects of reduced myocardial TIMP-3 may extend beyond MMP inhibition. TIMP-3 can inhibit enzymes that shed cell surface proteins such as TACE, the enzyme responsible for TNF-␣ bioactivation and secretion (4) . Myocardial TNF-␣ is elevated in heart failure patients, and cardiac-specific TNF-␣ overexpression in animals results in adverse matrix remodeling with progressive dilated cardiac failure (6) . Increased myocardial TACE activity is strongly associated with ventricular dilatation and cardiac dysfunction in human heart failure (30) . TNF-␣ contributes to the remodeling process in evolving heart failure through the local induction of specific MMPs and by stimulating programmed cell death (apoptosis) (7) . In addition, TIMP-3 may directly influence cell survival via a Fas-associated death domain-dependent mechanism (5, 12, 43) .
It is intriguing to speculate that reduced TIMP-3 not only increases MMP-mediated matrix fragmentation, but also increases activation and secretion of TNF-␣ by TACE, thereby promoting apoptosis in the failing heart. However, the contribution of each of these potential mechanisms to cardiac remodeling was not performed in this study. Future studies to investigate the independent role of constitutive TIMP-3 expression in regulating myocardial structure and function, perhaps with a mutant mouse model (12) , should prove illuminating.
Interestingly, recovery of TIMP-3 content in the failing myocardium is associated with reverse cardiac remodeling (18, 40) highlighting the influence of this critical matrix constituent in maintaining normal cardiac structure and function. The potential therapeutic benefit of TIMP-3 replacement in failing hearts remains unexplored. Therapeutic restoration of deficient myocardial TIMP-3, perhaps with gene or cell transfer, may prevent ventricular dilatation and decompensation in patients at risk of congestive heart failure.
In summary, TIMP-3 content is significantly reduced during the progression of heart failure in cardiomyo- pathic hamsters and is associated with adverse remodeling of the myocardial matrix. These results are consistent with end-stage human cardiomyopathy. These data suggest that TIMP-3 may contribute to the regulation of matrix remodeling and its reduction may promote a transition from compensated to end-stage congestive heart failure.
